Alnylam Pharmaceuticals
ALNY
#622
Rank
ยฃ25.18 B
Marketcap
ยฃ195.27
Share price
2.75%
Change (1 day)
36.74%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Revenue for Alnylam Pharmaceuticals (ALNY)

Revenue in 2024 (TTM): ยฃ1.63 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current revenue (TTM ) is ยฃ1.66 Billion. In 2023 the company made a revenue of ยฃ1.43 Billion an increase over the revenue in the year 2022 that were of ยฃ0.85 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Alnylam Pharmaceuticals from 2004 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) ยฃ1.63 B13.75%
2023 ยฃ1.43 B67.35%
2022 ยฃ0.85 B37.1%
2021 ยฃ0.62 B72.98%
2020 ยฃ0.36 B115.76%
2019 ยฃ0.16 B183.98%
2018 ยฃ59.01 M-11.3%
2017 ยฃ66.52 M74.07%
2016 ยฃ38.21 M37.82%
2015 ยฃ27.73 M-14.61%
2014 ยฃ32.47 M13.57%
2013 ยฃ28.59 M-30.73%
2012 ยฃ41.28 M-22.47%
2011 ยฃ53.24 M-17.84%
2010 ยฃ64.8 M4.31%
2009 ยฃ62.12 M-5.31%
2008 ยฃ65.61 M156.1%
2007 ยฃ25.62 M86.35%
2006 ยฃ13.74 M314.78%
2005 ยฃ3.31 M48.75%
2004 ยฃ2.22 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
ยฃ2.82 M-99.83%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ11.01 B 561.02%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ1.30 B-21.69%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.56 B-66.04%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ39.73 B 2,284.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
ยฃ42.56 B 2,454.29%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ13.34 B 700.60%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel